Roles of human papillomavirus in cancers: oncogenic mechanisms and clinical use
This study provides an overview of HPV-driven #Oncogenesis and explores how leveraging viral mechanisms can advance clinical diagnostics, prophylactic #Vaccination, and the implementation of targeted cancer therapies.
#STTT #OpenAccess: doi.org/10.1038/s413...
Targeting SRSF1 improves cancer immunotherapy by dually acting on CD8+T and tumor cells
SRSF1 inhibition enhances #Cancer #Immunotherapy by restoring CD8⁺ T-cell function and disrupting tumor metabolism, with TN2008 showing improved #Antitumor responses in preclinical models. @fudan-university.bsky.social
#STTT #OpenAccess: doi.org/10.1038/s413...
Identification of glutamine as a potential therapeutic target in dry eye disease
This study identified glutamine metabolism as a novel #TherapeuticTarget for #DryEyeDisease, showing that modulating #Glutaminolysis suppresses #OcularInflammation and restores metabolic homeostasis in the corneal epithelium.
#OpenAccess: doi.org/10.1038/s413...
Isoxazole-based molecules restore NK cell immune surveillance in hepatocarcinogenesis by targeting TM4SF5 and SLAMF7 linkage
#Isoxazole-based molecules enhance NK cell function by blocking TM4SF5–SLAMF7 interactions, restoring immune surveillance and suppressing HCC progression, thus offering a novel immunotherapy approach against #LiverCancer.
#STTT #OpenAccess: doi.org/10.1038/s413...
Cancer stem cells: landscape, challenges and emerging therapeutic innovations
This review examines the landscape of #CancerStemCells and their role in therapeutic resistance, highlighting emerging innovations in niche-targeted and #Epigenetic therapies to improve outcomes in #Cancer treatment.
#STTT #OpenAccess: doi.org/10.1038/s413...
🔬 Make sure you don't miss Cancer Researchers to Watch, an early career showcase designed by, and for, the next generation of cancer scientists.
Access to this event is only available to those who register by the early registration deadline of 21 April (tomorrow)!
Sign up at 2026.eacr.org/register
Call for Proposals: 2028 SMBE Regional Meetings, Europe
SMBE Call for 2028 Regional Meeting
🌍 European proposals
SMBE is calling for proposals for meetings and actions to be held Jan 1 - Dec 31 2028, in Europe.
🗓️ Deadline: May 15, 2026
📨 Proposal submission: members.smbe.org/membersurvey/Fill/P3R69Cbp
ℹ️ More information: smbe@am.kwglobal.com
#society
Relapse following allo-HSCT remains frequent and represents an ongoing therapeutic challenge for patients with myelofibrosis or BP-MPNs. @theebmt.bsky.social #EBMT26 #hematology #oncology
www.onclive.com/view/retrosp...
Neuro-immune crosstalk in cancer: mechanisms and therapeutic implications
This review analyzes the mechanisms of neuro-immune crosstalk in #Cancer, highlighting how neural signaling influences immune responses and offering insights into novel #TherapeuticTargets within the #TumorMicroenvironment.
#STTT #OpenAccess: doi.org/10.1038/s413...
Therapeutic potential of tumor-associated neutrophils: dual role and phenotypic plasticity
Tumor-associated neutrophils display dual roles in cancer, with phenotypic plasticity enabling shifts between antitumor and protumor states, offering novel targets for #Immunotherapy and #TumorMicroenvironment modulation.
#STTT #OpenAccess: doi.org/10.1038/s413...
High mtDNA content identifies oxidative phosphorylation-driven acute myeloid leukemias and represents a therapeutic vulnerability
High #mtDNA content characterizes #OxidativePhosphorylation-driven #AcuteMyeloidLeukemia, revealing a metabolic vulnerability that can be targeted with mitochondrial inhibitors to enhance therapeutic outcomes. @rug.nl
#STTT #OpenAccess: doi.org/10.1038/s413...
Welcome to Signal Transduction and Targeted Therapy (STTT) — a peer-reviewed, open-access Nature Portfolio journal publishing high-impact research across molecular biology, translational medicine, and targeted therapeutics.
Explore & submit: nature.com/sigtrans
Irinotecan alleviates chemoresistance to anthracyclines through the inhibition of AARS1-mediated BLM lactylation and homologous recombination repair
Irinotecan reverses #Anthracycline resistance by targeting AARS1-mediated BLM lactylation and homologous recombination repair, enhancing #DNAdamage sensitivity and improving therapeutic response in resistant #Cancers.
#STTT #OpenAccess: doi.org/10.1038/s413...
DDX39B K63-linked ubiquitination mediated by TRIM28 promotes NSCLC metastasis by enhancing ECAD lysosomal degradation
TRIM28-mediated ubiquitination of DDX39B promotes #LungCancer #Metastasis by enhancing the lysosomal degradation of E-cadherin, identifying a significant molecular mechanism and #TherapeuticTarget for advanced #NSCLC treatment.
#OpenAccess: doi.org/10.1038/s413...
Endoplasmic reticulum stress in disease pathogenesis: its implications for therapy
Review of the role of #ERstress in the #Pathogenesis of diverse human diseases, highlighting therapeutic approaches targeting the UPR to restore cellular homeostasis across #Cancer, metabolic, & #NeurodegenerativeDiseases.
#STTT #OpenAccess: doi.org/10.1038/s413...
Esophageal cancer: from pathogenesis to precision therapies
This review in #STTT explores #EsophagealCancer progression from molecular #Pathogenesis to precision therapies, emphasizing early detection, risk stratification, and advances in targeted and #Immunotherapy for improved clinical outcomes. #Medsky
#OpenAccess: doi.org/10.1038/s413...
HDAC inhibitor tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR-positive HER2-negative advanced breast cancer after CDK4/6 inhibitors treatment: clinical findings and exploratory circulating tumor cell and ctDNA biomarker analyses of a multicenter, phase 2 study (SYSUCC-020 trial)
The SYSUCC-020 trial shows that tucidinostat and metronomic capecitabine plus endocrine therapy offer a promising treatment for HR+/HER2- advanced #BreastCancer after CDK4/6 inhibitor progression, guided by #ctDNA #Biomarkers.
#STTT #OpenAccess: doi.org/10.1038/s413...
STRATEGIC-1: multiple-line, randomized, open-label GERCOR-PRODIGE-39 phase III trial in unresectable RAS/BRAF wild-type metastatic colorectal cancer
The STRATEGIC-1 trial assesses multi-line treatment sequencing in unresectable RAS/BRAF wild-type metastatic colorectal cancer to refine therapeutic strategies to optimize treatment sequencing and improve survival outcomes.
#OpenAccess: doi.org/10.1038/s413...
#PrecisionOncology #TargetedTherapy
WATCH: Alicia Morgans, MD, MPH, of
@danafarber.bsky.social
discusses the safety profile and AE management of mevrometostat in mCRPC. #oncology #pcsm #CRPC
www.onclive.com/view/dr-morg...
Tanja Kortemme's lab at @ucsanfrancisco.bsky.social focuses on AI and machine learning to engineer de novo proteins.
⏯️ Watch her #ASBMB26 talk, "I, biochemist: Automation & AI in the lab": youtu.be/uLQbaiTYIQY.
#AI #MachineLearning #ASBMB26
Free webinar: Epigenetic regulation & chromatin deregulation | 4/24 | 10 a.m. ET
Explore the cutting edge of epigenetic research and chromatin biology, featuring leading experts who are uncovering how gene regulation shapes health and disease.
➡️Register: www.asbmb.org/meetin....
#GeneRegulation
Immune modulatory vaccines targeting tumor microenvironment antigens: recent advances in oncology and beyond
This review outlines immune modulatory #Vaccines targeting #TumorMicroenvironment antigens, enhancing T-cell–mediated responses to overcome #Immunosuppression and improve #AntitumorImmunity.
#STTT #OpenAccess: doi.org/10.1038/s413...
Bioengineered iPSC-derived human macrophages with increased angiotensin-converting enzyme (ACE) expression suppress solid tumor growth
This study in #STTT shows ACE-enhanced iPSC-derived macrophages promote M1 polarization, enhance cytotoxic immune responses to boost #Antitumor immunity and suppress #SolidTumor growth, advancing #Immunotherapy approaches.
#OpenAccess: doi.org/10.1038/s413...
Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial
A phase III trial shows deutenzalutamide improves radiographic progression-free and overall survival with a favorable safety profile in metastatic castration-resistant #ProstateCancer following docetaxel and abiraterone failure. @fudan-university.bsky.social
#OpenAccess: doi.org/10.1038/s413...
Cortisol-resistant CAR-NK cells overcome steroid-induced immunosuppression in lung cancer
A rapid primary NK cell–based CAR screening platform combined with #circRNA-driven CAR expression enables durable, shed-resistant #Antitumor responses and improved persistence in #SolidTumor #Immunotherapy. @korea-institute-of-science-technology
#STTT #OpenAccess: doi.org/10.1038/s413...
A major multi-site clinical trial co-led by 🇺🇸 @washumedicine.bsky.social (senior author: @parpia.bsky.social) has shown that post-thrombotic syndrome — a common and often painful complication after deep vein #thrombosis — can be effectively treated with a minimally invasive #stent procedure.
Particle Metrix event roadmap for ISEV 2026 featuring team photos and schedule: Hands-on Demo (Apr 22), Booth #6 (Apr 23–26), and Lunch Presentation (Apr 24).
Counting down to #ISEV2026.
Meet the @Particle-Metrix.bsky.social team:
🗓️ Apr 22: Demo Corner - Hands-on with ZetaView® Evolution
🗓️ Apr 23-26: Booth #16 - Technical deep dives
🗓️ Apr 24: Lunch Presentation - Latest EV applications
See you in San Juan! 🇵🇷✨
#NanoparticleTrackingAnalysis @isev.org
📢 Calling fourth or fifth year #MedicalStudents looking to make an informed choice about their #Specialisation.
The #ESMOStudentCourse26 offers insights into #MedicalOncology, delivered by international experts.
📅 Apply by: 27 April 2026
🔗 https://ow.ly/UUir50YKhbK
Cortisol-resistant CAR-NK cells overcome steroid-induced immunosuppression in lung cancer
Engineered NR3C1-deleted CAR-NK cells bypass cortisol-mediated suppression restoring PI3K-AKT-NF-κB signaling and #Cytotoxicity to overcome steroid-induced #Immunosuppression and enhance tumor control in #LungCancer.
#STTT #OpenAccess: doi.org/10.1038/s413...
Irinotecan with trifluridine/tipiracil and bevacizumab for second-line metastatic colorectal cancer: a phase II multicenter study
Findings from a phase II study demonstrates that the combination of irinotecan with trifluridine/tipiracil and #Bevacizumab shows promising efficacy and tolerable safety as second-line therapy in metastatic #ColorectalCancer. #Medsky
#STTT #OpenAccess: doi.org/10.1038/s413...